Clinical Trial Search

Primary: Part 2: Number of Respiratory Failure-free Days (RFDs) From Randomization to Day 28 — 21.0; 21.0 days — p=0.6137

Primary: Percentage of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) — 250; 5…

Primary: Change From Baseline to Day 8 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Shedding — -2.88; -3.52; -3.75; -3.03 log10 copies/ml — p=0.4829

Primary: Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy — 69.1 percentage of participants — p=0.0003

Primary: Change in Weight — -3.8; 1.4 kg

Primary: Use of Parenteral Nutrition (Project A) — 62145 Participants

Primary: Number of Participants With Achievement of Hemostasis at 7 Minutes — 145; 149 Participants — p=0.005

Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants

Primary: Sensitivity and Specificity of InflammaDry Detector Compared to Clinical Assessment at Confirming a Diagnosis of Dry Eyes. — 85; 94 percentage of cases

Primary: Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant — 2.73; 2.77; 2.76; 2.27 units…

Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants

Primary: Percent of Participants With Grade 2 or Higher Toxicities — 80 percentage of participants

Primary: Percentage of Participants With Grade 3 or 4 Neutropenia — 19.4; 20.5 percentage of participants

Primary: Number of Participants With Pregnancy — 20; 30 Participants

Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants